Oncotelic Therapeutics, Inc. (OTLC)
USD 0.05
(-25.71%)
USD 0.05
(-25.71%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 18.4 Million USD | 8.75% |
| 2022 | 16.92 Million USD | 9.5% |
| 2021 | 15.45 Million USD | 38.21% |
| 2020 | 11.18 Million USD | 64.86% |
| 2019 | 6.78 Million USD | 484.25% |
| 2018 | 1.16 Million USD | -29.59% |
| 2017 | 1.64 Million USD | 2.17% |
| 2016 | 1.61 Million USD | -23.25% |
| 2015 | 2.1 Million USD | 48.2% |
| 2014 | 1.41 Million USD | 13.43% |
| 2013 | 1.25 Million USD | 38.85% |
| 2012 | 901 Thousand USD | -60.12% |
| 2011 | 2.25 Million USD | -79.13% |
| 2010 | 10.82 Million USD | 10.23% |
| 2009 | 9.81 Million USD | 56.04% |
| 2008 | 6.29 Million USD | 20.84% |
| 2007 | 5.2 Million USD | 23.33% |
| 2006 | 4.22 Million USD | 13.07% |
| 2005 | 3.73 Million USD | 42.41% |
| 2004 | 2.62 Million USD | -29.8% |
| 2003 | 3.73 Million USD | 4.38% |
| 2002 | 3.57 Million USD | -1.53% |
| 2001 | 3.63 Million USD | -63.96% |
| 2000 | 10.08 Million USD | -12.76% |
| 1999 | 11.55 Million USD | 312.75% |
| 1998 | 2.8 Million USD | 180.0% |
| 1997 | 1 Million USD | 42.86% |
| 1996 | 700 Thousand USD | 16.67% |
| 1995 | 600 Thousand USD | 100.0% |
| 1994 | 300 Thousand USD | -25.0% |
| 1993 | 400 Thousand USD | 100.0% |
| 1992 | 200 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 18.72 Million USD | 1.75% |
| 2024 Q2 | 18.43 Million USD | -1.57% |
| 2023 Q1 | 17.59 Million USD | 3.98% |
| 2023 FY | 18.4 Million USD | 8.75% |
| 2023 Q4 | 18.4 Million USD | 2.18% |
| 2023 Q3 | 18.01 Million USD | -0.42% |
| 2023 Q2 | 18.08 Million USD | 2.78% |
| 2022 Q1 | 16.8 Million USD | 8.76% |
| 2022 Q4 | 16.92 Million USD | 4.4% |
| 2022 FY | 16.92 Million USD | 9.5% |
| 2022 Q2 | 16.1 Million USD | -4.17% |
| 2022 Q3 | 16.21 Million USD | 0.64% |
| 2021 Q2 | 14.12 Million USD | 8.44% |
| 2021 Q1 | 13.02 Million USD | 16.49% |
| 2021 FY | 15.45 Million USD | 38.21% |
| 2021 Q3 | 14.8 Million USD | 4.78% |
| 2021 Q4 | 15.45 Million USD | 4.42% |
| 2020 Q4 | 11.18 Million USD | 27.6% |
| 2020 Q1 | 8.48 Million USD | 25.08% |
| 2020 Q2 | 8.21 Million USD | -3.16% |
| 2020 Q3 | 8.76 Million USD | 6.66% |
| 2020 FY | 11.18 Million USD | 64.86% |
| 2019 Q3 | 2.72 Million USD | 33.53% |
| 2019 Q2 | 2.04 Million USD | 74.05% |
| 2019 FY | 6.78 Million USD | 484.25% |
| 2019 Q4 | 6.78 Million USD | 148.61% |
| 2019 Q1 | 1.17 Million USD | 1.12% |
| 2018 FY | 1.16 Million USD | -29.59% |
| 2018 Q3 | 1.09 Million USD | -30.11% |
| 2018 Q4 | 1.16 Million USD | 6.42% |
| 2018 Q1 | 1.52 Million USD | -7.58% |
| 2018 Q2 | 1.56 Million USD | 2.43% |
| 2017 Q4 | 1.64 Million USD | 36.17% |
| 2017 FY | 1.64 Million USD | 2.17% |
| 2017 Q1 | 1.39 Million USD | -13.69% |
| 2017 Q2 | 1.42 Million USD | 2.3% |
| 2017 Q3 | 1.21 Million USD | -15.02% |
| 2016 Q3 | 1.48 Million USD | -8.16% |
| 2016 Q2 | 1.61 Million USD | -20.11% |
| 2016 FY | 1.61 Million USD | -23.25% |
| 2016 Q4 | 1.61 Million USD | 8.69% |
| 2016 Q1 | 2.02 Million USD | -3.76% |
| 2015 FY | 2.1 Million USD | 48.2% |
| 2015 Q3 | 1.69 Million USD | 45.63% |
| 2015 Q4 | 2.1 Million USD | 23.85% |
| 2015 Q1 | 1.02 Million USD | -27.48% |
| 2015 Q2 | 1.16 Million USD | 13.31% |
| 2014 Q3 | 1.67 Million USD | -14.07% |
| 2014 Q4 | 1.41 Million USD | -15.23% |
| 2014 Q2 | 1.94 Million USD | 39.64% |
| 2014 Q1 | 1.39 Million USD | 11.51% |
| 2014 FY | 1.41 Million USD | 13.43% |
| 2013 FY | 1.25 Million USD | 38.85% |
| 2013 Q4 | 1.25 Million USD | -17.43% |
| 2013 Q1 | 833 Thousand USD | -7.55% |
| 2013 Q2 | 891 Thousand USD | 6.96% |
| 2013 Q3 | 1.51 Million USD | 70.03% |
| 2012 FY | 901 Thousand USD | -60.12% |
| 2012 Q3 | 1.25 Million USD | -22.68% |
| 2012 Q4 | 901 Thousand USD | -27.98% |
| 2012 Q1 | 1.47 Million USD | -34.71% |
| 2012 Q2 | 1.61 Million USD | 9.69% |
| 2011 FY | 2.25 Million USD | -79.13% |
| 2011 Q4 | 2.25 Million USD | -24.14% |
| 2011 Q3 | 2.97 Million USD | 33.07% |
| 2011 Q2 | 2.23 Million USD | -20.16% |
| 2011 Q1 | 2.8 Million USD | -74.1% |
| 2010 FY | 10.82 Million USD | 10.23% |
| 2010 Q1 | 21.5 Million USD | 119.07% |
| 2010 Q2 | 11.66 Million USD | -45.78% |
| 2010 Q3 | 15.23 Million USD | 30.65% |
| 2010 Q4 | 10.82 Million USD | -28.97% |
| 2009 Q2 | 7.81 Million USD | 29.57% |
| 2009 Q1 | 6.03 Million USD | -4.16% |
| 2009 Q3 | 11.29 Million USD | 44.58% |
| 2009 Q4 | 9.81 Million USD | -13.08% |
| 2009 FY | 9.81 Million USD | 56.04% |
| 2008 Q4 | 6.29 Million USD | 3.23% |
| 2008 FY | 6.29 Million USD | 20.84% |
| 2008 Q1 | 5.06 Million USD | -2.69% |
| 2008 Q3 | 6.09 Million USD | -0.59% |
| 2008 Q2 | 6.13 Million USD | 21.0% |
| 2007 Q1 | 3.9 Million USD | -7.46% |
| 2007 FY | 5.2 Million USD | 23.33% |
| 2007 Q2 | 5.44 Million USD | 39.42% |
| 2007 Q3 | 4.95 Million USD | -9.05% |
| 2007 Q4 | 5.2 Million USD | 5.11% |
| 2006 Q4 | 4.22 Million USD | 4.95% |
| 2006 Q1 | 3.34 Million USD | -10.39% |
| 2006 Q2 | 4.04 Million USD | 20.83% |
| 2006 FY | 4.22 Million USD | 13.07% |
| 2006 Q3 | 4.02 Million USD | -0.49% |
| 2005 Q4 | 3.73 Million USD | -2.58% |
| 2005 Q3 | 3.83 Million USD | 55.62% |
| 2005 Q2 | 2.46 Million USD | -11.53% |
| 2005 Q1 | 2.78 Million USD | 6.18% |
| 2005 FY | 3.73 Million USD | 42.41% |
| 2004 Q3 | 3.27 Million USD | 4.17% |
| 2004 FY | 2.62 Million USD | -29.8% |
| 2004 Q1 | 3.74 Million USD | 0.16% |
| 2004 Q2 | 3.13 Million USD | -16.09% |
| 2004 Q4 | 2.62 Million USD | -19.82% |
| 2003 FY | 3.73 Million USD | 4.38% |
| 2003 Q4 | 3.73 Million USD | -0.43% |
| 2003 Q3 | 3.75 Million USD | 24.78% |
| 2003 Q2 | 3 Million USD | -2.66% |
| 2003 Q1 | 3.08 Million USD | -13.7% |
| 2002 Q1 | 3.79 Million USD | 4.49% |
| 2002 Q3 | 3.88 Million USD | 4.83% |
| 2002 Q2 | 3.7 Million USD | -2.4% |
| 2002 FY | 3.57 Million USD | -1.53% |
| 2002 Q4 | 3.57 Million USD | -7.9% |
| 2001 Q2 | 9.19 Million USD | -4.45% |
| 2001 FY | 3.63 Million USD | -63.96% |
| 2001 Q4 | 3.63 Million USD | -62.71% |
| 2001 Q1 | 9.62 Million USD | -4.53% |
| 2001 Q3 | 9.74 Million USD | 5.95% |
| 2000 Q1 | 10.85 Million USD | -6.07% |
| 2000 Q3 | 9.89 Million USD | -0.07% |
| 2000 Q4 | 10.08 Million USD | 1.92% |
| 2000 Q2 | 9.9 Million USD | -8.81% |
| 2000 FY | 10.08 Million USD | -12.76% |
| 1999 FY | 11.55 Million USD | 312.75% |
| 1999 Q1 | 2.9 Million USD | 3.57% |
| 1999 Q2 | 2.4 Million USD | -17.24% |
| 1999 Q3 | 1.7 Million USD | -29.17% |
| 1999 Q4 | 11.55 Million USD | 579.82% |
| 1998 Q3 | 4.4 Million USD | 100.0% |
| 1998 FY | 2.8 Million USD | 180.0% |
| 1998 Q1 | 1.6 Million USD | 60.0% |
| 1998 Q2 | 2.2 Million USD | 37.5% |
| 1998 Q4 | 2.8 Million USD | -36.36% |
| 1997 FY | 1 Million USD | 42.86% |
| 1997 Q2 | 900 Thousand USD | -35.71% |
| 1997 Q4 | 1 Million USD | -16.67% |
| 1997 Q3 | 1.2 Million USD | 33.33% |
| 1997 Q1 | 1.4 Million USD | 100.0% |
| 1996 Q4 | 700 Thousand USD | 40.0% |
| 1996 Q3 | 500 Thousand USD | -37.5% |
| 1996 FY | 700 Thousand USD | 16.67% |
| 1996 Q2 | 800 Thousand USD | -46.67% |
| 1996 Q1 | 1.5 Million USD | 150.0% |
| 1995 Q2 | 200 Thousand USD | -50.0% |
| 1995 Q1 | 400 Thousand USD | 33.33% |
| 1995 Q4 | 600 Thousand USD | 0.0% |
| 1995 FY | 600 Thousand USD | 100.0% |
| 1994 Q2 | 300 Thousand USD | 0.0% |
| 1994 Q4 | 300 Thousand USD | 0.0% |
| 1994 FY | 300 Thousand USD | -25.0% |
| 1993 Q3 | 300 Thousand USD | 0.0% |
| 1993 FY | 400 Thousand USD | 100.0% |
| 1993 Q4 | 400 Thousand USD | 33.33% |
| 1992 FY | 200 Thousand USD | 0.0% |
| 1992 Q4 | 200 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -66984.952% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -94.418% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 74.606% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -2175.414% |
| Rebus Holdings, Inc. | 5.24 Million USD | -251.076% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 68.815% |
| Qrons Inc. | 1.48 Million USD | -1136.196% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -1400.833% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 75.436% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -41074.635% |
| Skye Bioscience, Inc. | 14.07 Million USD | -30.778% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 65.475% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -92.062% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -4265.468% |
| SQZ Biotechnologies Company | 50.03 Million USD | 63.222% |
| Intellipharmaceutics International Inc. | 12 Million USD | -53.25% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -377.834% |
| Mesoblast Limited | 188.44 Million USD | 90.234% |
| Marizyme, Inc. | 26.67 Million USD | 31.011% |
| Genus plc | 485 Million USD | 96.205% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -214.986% |
| Pharming Group N.V. | 244.07 Million USD | 92.46% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -815.534% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -631.36% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -384.3% |
| ContraFect Corporation | 32.53 Million USD | 43.428% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -828.852% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -380.802% |
| IMV Inc. | 37.93 Million USD | 51.484% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -56.25% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1137549.521% |
| ONE Bio Corp. | 27.49 Million USD | 33.068% |
| Accustem Sciences Inc. | 1.07 Million USD | -1605.221% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 76.228% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -770.109% |
| Q BioMed Inc. | 8.13 Million USD | -126.282% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 77.81% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -257.623% |
| Biomind Labs Inc. | 1.49 Million USD | -1128.031% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 84.499% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -103.528% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1183.487% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -12851.487% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -9050.647% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -220.292% |
| GB Sciences, Inc. | 5.41 Million USD | -239.7% |
| Alpha Cognition Inc. | 7.16 Million USD | -156.86% |
| HST Global, Inc. | 593.59 Thousand USD | -3000.342% |
| CSL Limited | 18.62 Billion USD | 99.901% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -1361.525% |
| Halberd Corporation | 728.71 Thousand USD | -2425.447% |
| Enzolytics Inc. | 365.26 Million USD | 94.962% |
| Agentix Corp. | 2.51 Million USD | -633.042% |
| Resverlogix Corp. | 67.39 Million USD | 72.694% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -2094.195% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 95.864% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -973.711% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 25.631% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -54.61% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -402.117% |
| AVAX Technologies, Inc. | 3.99 Million USD | -360.806% |
| Zenith Capital Corp. | 27.56 Thousand USD | -66654.017% |
| Genscript Biotech Corporation | 1.32 Billion USD | 98.612% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -7611.337% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -392.82% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -2603.069% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -578.682% |
| Kadimastem Ltd | 3.5 Million USD | -425.082% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -27396.922% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 63.386% |
| BioStem Technologies, Inc. | 15.9 Million USD | -15.711% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -3860.287% |
| LadRx Corporation | 2.2 Million USD | -736.318% |
| Cell Source, Inc. | 15.8 Million USD | -16.428% |
| Regen BioPharma, Inc. | 5.45 Million USD | -237.206% |
| Regen BioPharma, Inc. | 5.45 Million USD | -237.206% |
| NovAccess Global Inc. | 7.86 Million USD | -134.118% |
| Affymax, Inc. | 8.87 Million USD | -107.456% |
| Itoco Inc. | 1.65 Million USD | -1013.233% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -797.043% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -204.239% |
| Mobile Lads Corp. | 1.31 Million USD | -1301.101% |
| CytoDyn Inc. | 127.89 Million USD | 85.61% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -43928.362% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1074.903% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -66.618% |
| SYBLEU INC | 681.41 Thousand USD | -2600.773% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -201.601% |
| International Stem Cell Corporation | 5.27 Million USD | -248.748% |
| Bioxytran, Inc. | 3.24 Million USD | -466.346% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -2840.74% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -298.59% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 55.109% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 17.344% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -808.637% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -235.951% |
| Neutra Corp. | 973.52 Thousand USD | -1790.382% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 36.573% |
| PureTech Health plc | 125.58 Million USD | 85.346% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -389.827% |
| IXICO plc | 1.9 Million USD | -868.452% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 10.354% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 82.189% |
| CSL Limited | 18.62 Billion USD | 99.901% |
| Cellectis S.A. | 249.36 Million USD | 92.62% |